14 research outputs found

    Circulating Apolipoprotein E Concentration and Cardiovascular Disease Risk: Meta-analysis of Results from Three Studies

    No full text
    <div><p>Background</p><p>The association of <i>APOE</i> genotype with circulating apolipoprotein E (ApoE) concentration and cardiovascular disease (CVD) risk is well established. However, the relationship of circulating ApoE concentration and CVD has received little attention.</p><p>Methods and Findings</p><p>To address this, we measured circulating ApoE concentration in 9,587 individuals (with 1,413 CVD events) from three studies with incident CVD events: two population-based studies, the English Longitudinal Study of Ageing (ELSA) and the men-only Northwick Park Heart Study II (NPHSII), and a nested sub-study of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT). We examined the association of circulating ApoE with cardiovascular risk factors in the two population-based studies (ELSA and NPHSII) and the relationship between ApoE concentration and coronary heart disease and stroke in all three studies. Analyses were carried out within study, and, where appropriate, pooled effect estimates were derived using meta-analysis. In the population-based samples, circulating ApoE was associated with systolic blood pressure (correlation coefficient 0.08, <i>p <</i> 0.001, in both ELSA and NPHSII), total cholesterol (correlation coefficient 0.46 and 0.34 in ELSA and NPHSII, respectively; both <i>p <</i> 0.001), low-density lipoprotein cholesterol (correlation coefficient 0.30 and 0.14, respectively; both <i>p <</i> 0.001), high-density lipoprotein (correlation coefficient 0.16 and −0.14, respectively; both <i>p <</i> 0.001), and triglycerides (correlation coefficient 0.43 and 0.46, respectivly; both <i>p <</i> 0.001). In NPHSII, ApoE concentration was additionally associated with apolipoprotein B (correlation coefficient 0.13, <i>p =</i> 0.001) and lipoprotein(a) (correlation coefficient −0.11, <i>p <</i> 0.001). In the pooled analysis of ASCOT, ELSA, and NPHSII, there was no association of ApoE with CVD events; the odds ratio (OR) for CVD events per 1-standard-deviation higher ApoE concentration was 1.02 (95% CI 0.96, 1.09). After adjustment for cardiovascular risk factors, the OR for CVD per 1-standard-deviation higher ApoE concentration was 0.97 (95% CI 0.82, 1.15). Limitations of these analyses include a polyclonal method of ApoE measurement, rather than isoform-specific measurement, a moderate sample size (although larger than any other study to our knowledge and with a long lag between ApoE measures), and CVD events that may attenuate an effect.</p><p>Conclusions</p><p>In the largest study to date on this question, we found no evidence of an association of circulating ApoE concentration with CVD events. The established association of <i>APOE</i> genotype with CVD events may be explained by isoform-specific functions as well as other mechanisms, rather than circulating concentrations of ApoE.</p></div

    Kaplan-Meier plot for tertiles of ApoE concentration in individuals with ε3ε3 genotype.

    No full text
    <p>This analysis was conducted to overcome any effect of isoform or structural change in the circulating protein. High concentrations are indicated in blue, intermediate in red, and low in green. Precise time-to-event measures are available in NPHSII, and therefore analyses are restricted to this study. There is a marginally statistically significant relationship between ApoE concentration and time to CVD event; however, given that this analysis is restricted to one study, which included only men, it has to be interpreted with caution. CVD, cardiovascular disease.</p
    corecore